Research Analysts Issue Forecasts for Amarin Co. plc’s Q3 2025 Earnings (NASDAQ:AMRN)

Amarin Co. plc (NASDAQ:AMRN) – Equities research analysts at Zacks Research cut their Q3 2025 EPS estimates for Amarin in a report released on Wednesday, June 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn ($0.06) per share for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Amarin’s current full-year earnings is ($0.18) per share. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.24) EPS and FY2026 earnings at ($0.14) EPS.

Amarin (NASDAQ:AMRN) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company had revenue of $56.52 million for the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative return on equity of 9.48% and a negative net margin of 18.96%. During the same quarter in the prior year, the company earned ($0.04) EPS.

AMRN has been the topic of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a research report on Tuesday, June 18th. StockNews.com lowered shares of Amarin from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Amarin has a consensus rating of “Hold” and an average target price of $1.08.

Amarin Stock Performance

Amarin stock opened at $0.69 on Monday. The stock has a market capitalization of $281.72 million, a price-to-earnings ratio of -5.72 and a beta of 1.95. Amarin has a 52-week low of $0.63 and a 52-week high of $1.49. The stock’s 50 day moving average price is $0.82 and its two-hundred day moving average price is $0.95.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP raised its position in Amarin by 74.4% in the 1st quarter. GSA Capital Partners LLP now owns 1,482,540 shares of the biopharmaceutical company’s stock valued at $1,321,000 after buying an additional 632,497 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Amarin by 104.8% in the first quarter. BNP Paribas Financial Markets now owns 932,173 shares of the biopharmaceutical company’s stock valued at $830,000 after purchasing an additional 476,996 shares during the last quarter. Simplicity Wealth LLC bought a new position in shares of Amarin during the first quarter valued at about $418,000. Hayek Kallen Investment Management boosted its holdings in Amarin by 63.3% during the fourth quarter. Hayek Kallen Investment Management now owns 1,016,760 shares of the biopharmaceutical company’s stock worth $885,000 after purchasing an additional 394,117 shares during the last quarter. Finally, Gilliland Jeter Wealth Management LLC bought a new stake in Amarin in the 4th quarter worth about $64,000. Institutional investors and hedge funds own 22.25% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.